Nexalis Therapeutics is a biotechnology company specialized in precision medicine delivered through inhalation.
CLINICAL TRIALS: Yes
IRX has 3 drugs under development:
IRX-211 is a treatment for breakthrough cancer pain.
IRX-616a is a treatment for panic disorder.
NEWS & PARTNERSHIPS
2022
The company was granted wholesale licences to sell and supplyscheduled substances, including all Schedule 2, 3, and 4 medications, as well as, limited Schedule 8 medications, including medical cannabis.
The company selected Ingenu as its contract research organization for its planned Complex Regional Pain Syndrome and Panic Disorder clinical trials.
2024
The company entered into a significant funding agreement up to $38.5 million AUD with Clendon Biotech Capital providing funding covering all direct costs associated with the Phase 1 & 2 clinical development of the Company’s key drugs: IRX-211 and IRX-616a.
2025
The company signed a $12,600,000 AUD facility with Linlithgow Family Office to drive SRX-25 drug development, the company’s oral Esketamine + CYP450 inhibitor fixed-dose combination therapy.
2026
The company changed its name from InhaleRX to Nexalis Therapeutics.
The company received $490k in Research & Development Tax Incentive for the year 2025.
The company signed a binding letter of intent with Point8 Capital replacing the Linlithgow Family Office facility. The non-dilutive funding amounts up to 53M AUD. The facility will be used to fund IRX-211, IRX-616a and IRX-SRX25.